![International Threat Of Housing Bubbles Deflates Sharply [Infographic]](https://businessaccessreport.com/wp-content/uploads/2023/09/1695528988_0x0-360x180.jpg)
Kakao Healthcare, the digital healthcare enterprise of South Korean web firm Kakao Company, has partnered with Novo Nordisk to additional develop its diabetes administration service powered by cell and AI applied sciences.
The 2 organisations just lately signed a memorandum of understanding to launch a wise healthcare service to assist sufferers with diabetes. In keeping with a press launch, Kakao Healthcare’s digital diabetes administration service, Challenge Gamma, will function the French medical system firm BIOCORP’s Mallya good sensor, which Novo Nordisk plans to launch in South Korea a while this yr.
Mallya, a wise sensor that attaches to a pre-filled insulin pen, will allow customers to mechanically acquire and file their each day insulin injection knowledge, together with the variety of insulin items and date and time. The info are transmitted through Bluetooth to the Challenge Gamma app the place sufferers can view their dosage logs in real-time, empowering sufferers to handle their very own circumstances anytime, anyplace.
Later, Mallya will likely be synced with the hospital info methods of the sufferers’ healthcare suppliers.
WHY IT MATTERS
This newest digital diabetes collaboration couldn’t come at a extra opportune time when diabetes circumstances are rising.
As we speak, there are about six million adults, or about one in each six folks, who reside with diabetes in South Korea, based mostly on the newest statistics supplied by the Korean Diabetes Affiliation. Their rely is predicted to rise because the inhabitants ages at a faster tempo.
THE LARGER TREND
Kakao Healthcare has been concerned in each native and worldwide initiatives to assist sufferers with diabetes by selling digital diabetes administration. Its collaboration with Novo Nordisk adopted its latest signing of a world partnership with Dexcom to arrange a diabetes administration service beginning in South Korea later this yr.
In the meantime, Novo Nordisk tied up with Health2Sync in Taiwan to allow the latter’s cell well being app to sync dose logs from the NovoPen good insulin pens, in addition to supply a affected person assist programme.
ON THE RECORD
“South Korea is without doubt one of the nations with probably the most superior digital atmosphere on the earth, and specifically, its healthcare AI innovation is surprisingly dynamic and thrilling. Sadly, nevertheless, South Korea is ageing on the quickest tempo on the earth, and the variety of Korean sufferers with diabetes can also be growing. We’re more than happy to kind a strategic alliance with Kakao Healthcare, a pacesetter within the home digital well being area, and work collectively to offer sensible options that may enhance the well being of six million Koreans affected by diabetes,” Novo Nordisk President Sacha Semienchuk mentioned in an announcement.
“Via our collaboration with Novo Nordisk, sufferers with diabetes, whether or not at house or overseas, will have the ability to handle their well being extra simply and conveniently,” Kakao Healthcare CEO Hwang Hee additionally commented.
